ArriVent BioPharma, Inc.'s total assets for Q2 2025 were $269.51M, an increase of 25.06% from the previous quarter. AVBP total liabilities were $19.64M for the fiscal quarter, a 51.59% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.